1. Home
  2. LOAN vs MAIA Comparison

LOAN vs MAIA Comparison

Compare LOAN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOAN
  • MAIA
  • Stock Information
  • Founded
  • LOAN 1989
  • MAIA 2018
  • Country
  • LOAN United States
  • MAIA United States
  • Employees
  • LOAN N/A
  • MAIA N/A
  • Industry
  • LOAN Real Estate Investment Trusts
  • MAIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOAN Real Estate
  • MAIA Health Care
  • Exchange
  • LOAN Nasdaq
  • MAIA Nasdaq
  • Market Cap
  • LOAN 61.5M
  • MAIA 56.3M
  • IPO Year
  • LOAN 1999
  • MAIA 2022
  • Fundamental
  • Price
  • LOAN $5.49
  • MAIA $1.52
  • Analyst Decision
  • LOAN
  • MAIA
  • Analyst Count
  • LOAN 0
  • MAIA 0
  • Target Price
  • LOAN N/A
  • MAIA N/A
  • AVG Volume (30 Days)
  • LOAN 23.8K
  • MAIA 539.4K
  • Earning Date
  • LOAN 07-22-2025
  • MAIA 08-12-2025
  • Dividend Yield
  • LOAN 8.42%
  • MAIA N/A
  • EPS Growth
  • LOAN N/A
  • MAIA N/A
  • EPS
  • LOAN 0.48
  • MAIA N/A
  • Revenue
  • LOAN $7,300,469.00
  • MAIA N/A
  • Revenue This Year
  • LOAN N/A
  • MAIA N/A
  • Revenue Next Year
  • LOAN $4.47
  • MAIA N/A
  • P/E Ratio
  • LOAN $11.44
  • MAIA N/A
  • Revenue Growth
  • LOAN N/A
  • MAIA N/A
  • 52 Week Low
  • LOAN $4.74
  • MAIA $1.40
  • 52 Week High
  • LOAN $6.05
  • MAIA $3.74
  • Technical
  • Relative Strength Index (RSI)
  • LOAN 53.57
  • MAIA 34.15
  • Support Level
  • LOAN $5.40
  • MAIA $1.68
  • Resistance Level
  • LOAN $5.54
  • MAIA $1.89
  • Average True Range (ATR)
  • LOAN 0.17
  • MAIA 0.09
  • MACD
  • LOAN -0.01
  • MAIA -0.02
  • Stochastic Oscillator
  • LOAN 42.30
  • MAIA 11.63

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: